In cohorts of advanced NSCLC with no prior ICI exposure treated with αPD‐(L)1 inhibitors, higher frequencies of circulating CD56+ PD‐1+ NK cells at baseline were associated with improved OS and greater CD25 (IL2Rα) expression on CD56+ NK cells after two cycles of chemoIO was associated with clinical benefit.73, 74. This evidence concerns the gene NCAM1 and non-small cell lung carcinoma.